CA2869562C
(en)
|
2012-04-11 |
2023-09-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors targeting b-cell maturation antigen
|
JP6636803B2
(en)
|
2013-02-05 |
2020-01-29 |
エンクマフ エスアーエールエル |
Method for selection of antibodies to BCMA
|
AU2014236726A1
(en)
|
2013-03-14 |
2015-09-17 |
Bellicum Pharmaceuticals, Inc. |
Methods for controlling T cell proliferation
|
KR102238226B1
(en)
|
2013-05-14 |
2021-04-09 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
Human application of engineered chimeric antigen receptor (car) t-cells
|
GB201317929D0
(en)
|
2013-10-10 |
2013-11-27 |
Ucl Business Plc |
Chimeric antigen receptor
|
AU2014348657A1
(en)
*
|
2013-11-13 |
2016-05-19 |
Novartis Ag |
mTOR inhibitors for enhancing the immune response
|
ES2792849T3
(en)
|
2014-02-10 |
2020-11-12 |
Univ Emory |
Expression of chemical polypeptide with variable lymphocyte receptors in immune cells and uses to treat cancer
|
EP3105335B1
(en)
|
2014-02-14 |
2019-10-02 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors and methods of making
|
EP3104866A4
(en)
*
|
2014-02-14 |
2017-08-02 |
Bellicum Pharmaceuticals, Inc. |
Methods for activating t cells using an inducible chimeric polypeptide
|
CA2939411A1
(en)
|
2014-02-27 |
2015-09-03 |
Ucl Business Plc |
Ligand
|
TR201910814T4
(en)
*
|
2014-03-19 |
2019-08-21 |
Cellectis |
Cd123 specific chimeric antigen receptors for cancer immunotherapy.
|
CA2945305C
(en)
|
2014-04-10 |
2023-10-17 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Method and compositions for cellular immunotherapy
|
AU2015248956B2
(en)
*
|
2014-04-14 |
2020-06-25 |
Cellectis |
BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy
|
CN106536549B
(en)
*
|
2014-04-25 |
2020-01-17 |
蓝鸟生物公司 |
MND promoter chimeric antigen receptor
|
DK3134095T3
(en)
*
|
2014-04-25 |
2020-06-29 |
Bluebird Bio Inc |
IMPROVED PROCEDURES FOR THE PREPARATION OF ADOPTIVE CELL THERAPIES
|
CA2984484C
(en)
|
2014-05-02 |
2024-01-23 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of chimeric autoantibody receptor t cells
|
CN106536564B
(en)
*
|
2014-06-02 |
2021-08-31 |
美国卫生和人力服务部 |
Chimeric antigen receptor targeting CD-19
|
ES2846811T3
(en)
*
|
2014-06-06 |
2021-07-29 |
Bluebird Bio Inc |
Improved T cell compositions
|
US10982189B2
(en)
*
|
2014-07-11 |
2021-04-20 |
Celgene Corporation |
Methods of improving vector transduction efficiency into T lymphocytes
|
MA40253A
(en)
|
2014-07-15 |
2017-05-24 |
Juno Therapeutics Inc |
Engineered cells for adoptive cell therapy
|
TWI718992B
(en)
|
2014-07-21 |
2021-02-21 |
瑞士商諾華公司 |
Treatment of cancer using a cll-1 chimeric antigen receptor
|
CN106687483B
(en)
*
|
2014-07-21 |
2020-12-04 |
诺华股份有限公司 |
Treatment of cancer using humanized anti-BCMA chimeric antigen receptors
|
JP6706244B2
(en)
*
|
2014-07-24 |
2020-06-03 |
ブルーバード バイオ, インコーポレイテッド |
BCMA chimeric antigen receptor
|
JP6721568B2
(en)
*
|
2014-07-29 |
2020-07-15 |
セレクティスCellectis |
ROR1 (NTRKR1)-specific chimeric antigen receptor for cancer immunotherapy
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
US10888608B2
(en)
|
2014-09-02 |
2021-01-12 |
Bellicum Pharmaceuticals, Inc. |
Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
EP3029068A1
(en)
|
2014-12-03 |
2016-06-08 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
|
EP4310097A3
(en)
*
|
2014-12-05 |
2024-04-03 |
Memorial Sloan Kettering Cancer Center |
Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
|
SI3226897T1
(en)
|
2014-12-05 |
2021-08-31 |
Memorial Sloan Kettering Cancer Center |
Antibodies targeting b-cell maturation antigen and methods of use
|
SI3628687T1
(en)
|
2014-12-12 |
2021-12-31 |
2Seventy Bio, Inc. |
Bcma chimeric antigen receptors
|
JP2018504894A
(en)
*
|
2014-12-19 |
2018-02-22 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Chimeric antigen receptor and method of use thereof
|
EP3556768A1
(en)
|
2014-12-24 |
2019-10-23 |
Aadigen, LLC |
Peptides and nanoparticles for intracellular delivery of molecules
|
MX2017009181A
(en)
*
|
2015-01-26 |
2017-11-22 |
Cellectis |
ANTI-CLL1 SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGEN RECEPTORS (scCARS) FOR CANCER IMMUNOTHERAPY.
|
WO2016154055A1
(en)
*
|
2015-03-20 |
2016-09-29 |
Bluebird Bio, Inc. |
Vector formulations
|
CA2981142A1
(en)
|
2015-03-27 |
2016-10-06 |
University Of Southern California |
Car t-cell therapy directed to lhr for the treatment of solid tumors
|
PE20171653A1
(en)
*
|
2015-04-13 |
2017-11-13 |
Pfizer |
CHEMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN
|
CN114773476A
(en)
|
2015-04-13 |
2022-07-22 |
辉瑞公司 |
Therapeutic antibodies and their use
|
CN108136021A
(en)
|
2015-04-25 |
2018-06-08 |
综合医院公司 |
For the anti-property the driven away reagent and anti-cancer agent in conjunction therapy and composition for the treatment of cancer
|
GB201507119D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic Acid Construct
|
CN107995913B
(en)
|
2015-05-18 |
2022-02-11 |
T细胞受体治疗公司 |
Compositions and methods for reprogramming TCRs using fusion proteins
|
WO2016185443A1
(en)
|
2015-05-20 |
2016-11-24 |
Novartis Ag |
Pharmaceutical combination of everolimus with dactolisib
|
EP3302559B1
(en)
*
|
2015-06-04 |
2022-01-12 |
University of Southern California |
Lym-1 and lym-2 targeted car cell immunotherapy
|
CN107708741A
(en)
*
|
2015-06-12 |
2018-02-16 |
免疫医疗公司 |
The physics carried out with the T cell (CAR T) or NK cells (CAR NK) of Chimeric antigen receptor (CAR) construct and expression CAR constructs
|
HUE054201T2
(en)
|
2015-06-19 |
2021-08-30 |
Endres Stefan Prof Dr |
Pd-1-cd28 fusion proteins and their use in medicine
|
MA42895A
(en)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
|
SI3331910T1
(en)
|
2015-08-03 |
2020-07-31 |
Engmab Sarl |
Monoclonal antibodies against human b cell maturation antigen (bcma)
|
CA2994829A1
(en)
|
2015-08-07 |
2017-02-16 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Bispecific car t-cells for solid tumor targeting
|
CN105384825B
(en)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
A kind of bispecific chimeric antigen receptor and its application based on single domain antibody
|
JP7010487B2
(en)
|
2015-08-17 |
2022-03-03 |
ソウル大学校産学協力団 |
Chimeric antigen receptor linked with anti-cotinine antibody and its use
|
WO2017049208A1
(en)
|
2015-09-18 |
2017-03-23 |
The General Hospital Corporation Dba Massachusetts General Hospital |
Localized delivery of anti-fugetactic agent for treatment of cancer
|
ES2895901T3
(en)
|
2015-10-16 |
2022-02-23 |
Univ Muenchen Ludwig Maximilians |
CXCR6-transduced T cells for targeted tumor therapy
|
WO2017070042A1
(en)
|
2015-10-20 |
2017-04-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of producing t cell populations using akt inhibitors
|
KR20190008171A
(en)
|
2015-11-13 |
2019-01-23 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
Anti-BCMA polypeptides and proteins
|
WO2017088623A1
(en)
*
|
2015-11-26 |
2017-06-01 |
广州中科蓝华生物科技有限公司 |
Anti-placenta-chondroitin-sulfate chimeric antigen receptor and application thereof
|
AU2016361451B2
(en)
|
2015-11-27 |
2024-01-25 |
Cartherics Pty. Ltd. |
Genetically modified cells and uses thereof
|
US11479755B2
(en)
|
2015-12-07 |
2022-10-25 |
2Seventy Bio, Inc. |
T cell compositions
|
EP3184548A1
(en)
*
|
2015-12-23 |
2017-06-28 |
Miltenyi Biotec GmbH |
Chimeric antigen receptor with cytokine receptor activating or blocking domain
|
US11571469B2
(en)
|
2016-01-07 |
2023-02-07 |
Mayo Foundation For Medical Education And Research |
Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression
|
US11090334B2
(en)
|
2016-01-29 |
2021-08-17 |
Med Manor Organics (P) Ltd. |
Chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
|
WO2017139199A1
(en)
|
2016-02-10 |
2017-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Inducible arginase
|
CN109414455B
(en)
*
|
2016-04-01 |
2023-01-20 |
凯德药业股份有限公司 |
BCMA binding molecules and methods of use thereof
|
SI3436079T1
(en)
|
2016-04-01 |
2022-01-31 |
Kite Pharma, Inc. |
Chimeric antigen and t cell receptors and methods of use
|
WO2017173384A1
(en)
|
2016-04-01 |
2017-10-05 |
Kite Pharma, Inc. |
Chimeric receptors and methods of use thereof
|
JP2019519529A
(en)
|
2016-05-27 |
2019-07-11 |
アメリカ合衆国 |
FLT3-specific chimeric antigen receptor and method of using the same
|
SG11201810697QA
(en)
|
2016-06-07 |
2018-12-28 |
Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft |
Chimeric antigen receptor and car-t cells that bind bcma
|
BR112018077375A2
(en)
|
2016-06-30 |
2019-10-01 |
F. Hoffmann-La Roche Ag |
trivalent bispecific antibody molecules, pharmaceutical composition, expression vector, host cell and method for producing a trivalent bispecific antibody molecule
|
CA3032498A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
BR112019004711A2
(en)
*
|
2016-09-14 |
2019-05-28 |
Janssen Biotech Inc |
chimeric antigen receptors comprising bcma specific type III fibronectin domains and uses thereof
|
IL302917A
(en)
|
2016-10-07 |
2023-07-01 |
Tcr2 Therapeutics Inc |
Compositions and methods for t-cell receptors reprogramming using fusion proteins
|
CN108004259B
(en)
*
|
2016-11-02 |
2020-06-30 |
上海恒润达生生物科技有限公司 |
Chimeric antigen receptor targeting B cell maturation antigen and uses thereof
|
BR112019008426A2
(en)
|
2016-11-02 |
2019-09-03 |
Engmab Sarl |
bispecific antibody against bcma and cd3 and an immunological drug for combined use in the treatment of multiple myeloma
|
EP3544996A2
(en)
|
2016-11-22 |
2019-10-02 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
BR112019010470A2
(en)
|
2016-11-23 |
2019-09-10 |
Novartis Ag |
immune response enhancement methods with everolimus, dactolisib or both
|
AU2017368320A1
(en)
*
|
2016-12-02 |
2019-05-02 |
Cartesian Therapeutics, Inc. |
Cancer immuno therapy with highly enriched CD8+ chimeric antigen receptor T cells
|
US11408005B2
(en)
|
2016-12-12 |
2022-08-09 |
Seattle Children's Hospital |
Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
|
WO2018128485A1
(en)
*
|
2017-01-05 |
2018-07-12 |
한국생명공학연구원 |
Natural killer cell expressing anti-cotinine chimeric antigen receptor
|
EP3577134A1
(en)
|
2017-01-31 |
2019-12-11 |
Novartis AG |
Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
|
EP3579870A4
(en)
|
2017-02-07 |
2020-12-30 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
|
CA3052779A1
(en)
*
|
2017-02-17 |
2018-08-23 |
Fred Hutchinson Cancer Research Center |
Combination therapies for treatment of bcma-related cancers and autoimmune disorders
|
US11850262B2
(en)
|
2017-02-28 |
2023-12-26 |
Purdue Research Foundation |
Compositions and methods for CAR T cell therapy
|
WO2018175676A1
(en)
|
2017-03-23 |
2018-09-27 |
The General Hospital Corporation |
Cxcr4/cxcr7 blockade and treatment of human papilloma virus-associated disease
|
CA3058425A1
(en)
*
|
2017-03-28 |
2018-10-04 |
The Trustees Of The University Of Pennsylvania |
Methods to protect transplanted tissue from rejection
|
AU2018243571B2
(en)
|
2017-03-31 |
2024-03-07 |
The Board Of Trustees Of The Leland Standford Junior University |
Methods of treating T cell exhaustion by inhibiting or modulating T cell receptor signaling
|
EP3612210A4
(en)
|
2017-04-19 |
2021-01-27 |
Board Of Regents, The University Of Texas System |
Immune cells expressing engineered antigen receptors
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
WO2018201051A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
CA3061945A1
(en)
|
2017-05-01 |
2018-11-08 |
Juno Therapeutics, Inc. |
Combination of a cell therapy and an immunomodulatory compound
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
JP7356354B2
(en)
|
2017-05-12 |
2023-10-04 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
Materials and methods for the manipulation of cells and their use in immuno-oncology
|
EP3638218A4
(en)
|
2017-06-14 |
2021-06-09 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
WO2019000223A1
(en)
*
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
Chimeric antibody immune effctor cell engagers and methods of use thereof
|
JP7288405B2
(en)
*
|
2017-06-30 |
2023-06-07 |
アメリカ合衆国 |
Anti-B cell maturation antigen chimeric antigen receptor with human domain
|
CR20200100A
(en)
|
2017-08-01 |
2020-05-09 |
Medimmune Llc |
Bcma monoclonal antibody-drug conjugate
|
CA3075714A1
(en)
|
2017-09-14 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer
|
JP2020533380A
(en)
|
2017-09-14 |
2020-11-19 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
Combination treatment of cancer
|
JP2020533383A
(en)
|
2017-09-14 |
2020-11-19 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
Combination treatment of cancer
|
KR20200055037A
(en)
|
2017-09-19 |
2020-05-20 |
메사추세츠 인스티튜트 오브 테크놀로지 |
Compositions and uses for chimeric antigen receptor T cell therapy
|
US20200316122A1
(en)
|
2017-10-11 |
2020-10-08 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Methods of producing t cell populations using p38 mapk inhibitors
|
TWI829655B
(en)
|
2017-10-18 |
2024-01-21 |
瑞士商諾華公司 |
Compositions and methods for selective protein degradation
|
US11851679B2
(en)
|
2017-11-01 |
2023-12-26 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
KR20200116077A
(en)
|
2017-11-01 |
2020-10-08 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Chimeric antigen receptor and coding polynucleotide specific for B cell maturation antigen
|
CA3080904A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
|
CN109748968B
(en)
*
|
2017-11-03 |
2020-12-01 |
西安宇繁生物科技有限责任公司 |
BCMA specific chimeric antigen receptor T cell and application thereof
|
WO2019090364A1
(en)
|
2017-11-06 |
2019-05-09 |
Juno Therapeutics, Inc. |
Combination of a cell therapy and a gamma secretase inhibitor
|
EP3710039A4
(en)
|
2017-11-13 |
2021-08-04 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
|
JP2021502979A
(en)
|
2017-11-15 |
2021-02-04 |
ノバルティス アーゲー |
BCMA targeting chimeric antigen receptor, CD19 targeting chimeric antigen receptor and combination therapy
|
CA3083118A1
(en)
|
2017-11-22 |
2019-05-31 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
KR20200096253A
(en)
|
2017-11-30 |
2020-08-11 |
노파르티스 아게 |
BCMA-targeting chimeric antigen receptor, and uses thereof
|
AU2018393110B2
(en)
*
|
2017-12-20 |
2023-04-27 |
Poseida Therapeutics, Inc. |
VCAR compositions and methods for use
|
CN109971715A
(en)
*
|
2017-12-28 |
2019-07-05 |
深圳华大生命科学研究院 |
A kind of cultural method of specific amplification CAR-T cell
|
CN109971716B
(en)
*
|
2017-12-28 |
2023-08-01 |
上海细胞治疗研究院 |
EGFR-specific CAR-T cells from autocrine CD47 antibodies and uses thereof
|
CN112218651A
(en)
|
2018-01-08 |
2021-01-12 |
诺华公司 |
Immunopotentiating RNA for combination with chimeric antigen receptor therapy
|
TW201940182A
(en)
|
2018-01-22 |
2019-10-16 |
美商安德賽特公司 |
Methods of use for CAR T cells
|
US20210038659A1
(en)
|
2018-01-31 |
2021-02-11 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
JP6968389B2
(en)
*
|
2018-02-01 |
2021-11-17 |
南京馴鹿医療技術有限公司 |
Chimeric antigen receptor (CAR) that binds to BCMA and its applications
|
TWI728309B
(en)
*
|
2018-02-01 |
2021-05-21 |
大陸商南京馴鹿醫療技術有限公司 |
A chimeric antigen receptor (car) binding to bcma and use thereof
|
US20210052647A1
(en)
|
2018-02-09 |
2021-02-25 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Tethered interleukin-15 and interleukin-21
|
US10596165B2
(en)
|
2018-02-12 |
2020-03-24 |
resTORbio, Inc. |
Combination therapies
|
CN110157675B
(en)
*
|
2018-02-12 |
2022-05-27 |
深圳宾德生物技术有限公司 |
Targeting T lymphocyte and preparation method and application thereof
|
WO2019160956A1
(en)
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
CN110372796B
(en)
*
|
2018-04-12 |
2023-05-02 |
上海赛比曼生物科技有限公司 |
Chimeric antigen receptor targeting BCMA and preparation method and application thereof
|
WO2019209715A1
(en)
|
2018-04-24 |
2019-10-31 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of producing t cell populations using hydroxycitric acid and/or a salt thereof
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
EP3790629A1
(en)
|
2018-05-11 |
2021-03-17 |
CRISPR Therapeutics AG |
Methods and compositions for treating cancer
|
AU2019277029C1
(en)
|
2018-06-01 |
2024-01-04 |
Novartis Ag |
Binding molecules against BCMA and uses thereof
|
US20210371932A1
(en)
|
2018-06-01 |
2021-12-02 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
WO2019241426A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
Bcma chimeric antigen receptors and uses thereof
|
WO2020047449A2
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
EP3844267A2
(en)
|
2018-08-31 |
2021-07-07 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
JP2022502037A
(en)
|
2018-09-28 |
2022-01-11 |
マサチューセッツ インスティテュート オブ テクノロジー |
Immunomodulatory molecules localized to collagen and their methods
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
US20210379057A1
(en)
|
2018-10-16 |
2021-12-09 |
Massachusetts Institute Of Technology |
Nutlin-3a for use in treating a mycobacterium tuberculosis infection
|
US20200190163A1
(en)
*
|
2018-10-26 |
2020-06-18 |
Lijun Wu |
Humanized bcma-car-t cells
|
WO2020092455A2
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
WO2020089794A1
(en)
|
2018-10-31 |
2020-05-07 |
Glaxosmithkline Intellectual Property Development Limited |
Methods of treating cancer
|
WO2020092854A2
(en)
|
2018-11-01 |
2020-05-07 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
|
AU2019377854A1
(en)
|
2018-11-08 |
2021-05-27 |
Juno Therapeutics, Inc. |
Methods and combinations for treatment and T cell modulation
|
BR112021012172A2
(en)
|
2018-12-12 |
2021-08-31 |
Kite Pharma, Inc. |
CHIMERIC AND T-CELL ANTIGEN RECEPTORS AND METHODS OF USE
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
SG11202009283QA
(en)
|
2019-01-16 |
2020-10-29 |
Caribou Biosciences Inc |
Humanized bcma antibody and bcma-car-t cells
|
SG11202108655TA
(en)
|
2019-02-15 |
2021-09-29 |
Univ Southern California |
Lym-1 and lym-2 antibody compositions and improved car constructs
|
EP3930763A1
(en)
|
2019-02-25 |
2022-01-05 |
Novartis AG |
Mesoporous silica particles compositions for viral delivery
|
KR20210136050A
(en)
|
2019-03-01 |
2021-11-16 |
이오반스 바이오테라퓨틱스, 인크. |
Expansion of tumor-infiltrating lymphocytes from liquid tumors and their therapeutic use
|
WO2020182681A1
(en)
|
2019-03-08 |
2020-09-17 |
Klinikum Der Universität München |
Ccr8 expressing lymphocytes for targeted tumor therapy
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
WO2020190737A1
(en)
*
|
2019-03-15 |
2020-09-24 |
Cartesian Therapeutics, Inc. |
Anti-bcma chimeric antigen receptors
|
US20220142948A1
(en)
|
2019-03-18 |
2022-05-12 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
WO2020191316A1
(en)
|
2019-03-21 |
2020-09-24 |
Novartis Ag |
Car-t cell therapies with enhanced efficacy
|
US20220195397A1
(en)
|
2019-04-04 |
2022-06-23 |
Shanghai Pharmaceuticals Holding Co., Ltd. |
Immune cell containing tumor antigen recognition receptor and application thereof
|
EP3953455A1
(en)
|
2019-04-12 |
2022-02-16 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
WO2020219742A1
(en)
|
2019-04-24 |
2020-10-29 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
US20220249558A1
(en)
|
2019-04-30 |
2022-08-11 |
Crispr Therapeutics Ag |
Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
|
EP3733707A1
(en)
|
2019-04-30 |
2020-11-04 |
Celyad S.A. |
Car t-cells targeting bcma and uses thereof
|
WO2020224606A1
(en)
|
2019-05-07 |
2020-11-12 |
亘喜生物科技(上海)有限公司 |
Engineered immune cell targeting bcma and use thereof
|
WO2020236967A1
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Random crispr-cas deletion mutant
|
EP3990491A1
(en)
|
2019-06-26 |
2022-05-04 |
Massachusetts Institute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
KR20220068984A
(en)
|
2019-07-30 |
2022-05-26 |
상하이 한서 바이오메디컬 컴퍼니 리미티드 |
Anti-BCMA antibodies, antigen-binding fragments thereof and medical uses thereof
|
CN114502593A
(en)
|
2019-08-06 |
2022-05-13 |
葛兰素史密斯克莱知识产权发展有限公司 |
Biopharmaceutical compositions and related methods
|
WO2021030627A1
(en)
|
2019-08-13 |
2021-02-18 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
WO2021033089A1
(en)
|
2019-08-16 |
2021-02-25 |
Janssen Biotech, Inc. |
Therapeutic immune cells with improved function and methods for making the same
|
CN112409482B
(en)
*
|
2019-08-20 |
2022-08-26 |
杭州尚健生物技术有限公司 |
BCMA antibodies
|
WO2021041922A1
(en)
|
2019-08-30 |
2021-03-04 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
EP4031577A4
(en)
*
|
2019-09-18 |
2023-12-20 |
Board of Regents, The University of Texas System |
A method of engineering natural killer-cells to target bcma-positive tumors
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
CN110642953B
(en)
*
|
2019-10-12 |
2021-09-17 |
华夏源(上海)细胞基因工程股份有限公司 |
BCMA-targeted T cell receptor fusion protein and application thereof
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
EP4065158A2
(en)
|
2019-11-26 |
2022-10-05 |
Novartis AG |
Chimeric antigen receptors binding bcma and cd19 and uses thereof
|
WO2021132746A1
(en)
*
|
2019-12-24 |
2021-07-01 |
Abl Bio, Inc. |
Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof
|
US20230028399A1
(en)
*
|
2020-01-13 |
2023-01-26 |
Nkarta, Inc. |
Bcma-directed cellular immunotherapy compositions and methods
|
CA3173394A1
(en)
|
2020-02-27 |
2021-09-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
EP4110377A2
(en)
|
2020-02-27 |
2023-01-04 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
CN115768464A
(en)
|
2020-03-10 |
2023-03-07 |
麻省理工学院 |
Methods of generating engineered memory-like NK cells and compositions thereof
|
IL296241A
(en)
|
2020-03-10 |
2022-11-01 |
Massachusetts Inst Technology |
Compositions and methods for immunotherapy of npm1c-positive cancer
|
KR102371151B1
(en)
*
|
2020-03-13 |
2022-03-07 |
주식회사 큐로셀 |
Anti-bcma-binding domains, fusion proteins comprising thereof, and compositions comprising thereof
|
EP4142723A2
(en)
|
2020-04-28 |
2023-03-08 |
Juno Therapeutics, Inc. |
Combination of bcma-directed t cell therapy and an immunomodulatory compound
|
WO2021221783A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
WO2021221782A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
KR102400977B1
(en)
|
2020-05-29 |
2022-05-25 |
성균관대학교산학협력단 |
Method for processing page fault by a processor
|
EP4165169A1
(en)
|
2020-06-11 |
2023-04-19 |
Novartis AG |
Zbtb32 inhibitors and uses thereof
|
WO2022035793A1
(en)
*
|
2020-08-10 |
2022-02-17 |
Precision Biosciences, Inc. |
Antibodies and fragments specific for b-cell maturation antigen and uses thereof
|
WO2022040586A2
(en)
|
2020-08-21 |
2022-02-24 |
Novartis Ag |
Compositions and methods for in vivo generation of car expressing cells
|
WO2022055946A1
(en)
|
2020-09-08 |
2022-03-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T cell phenotypes associated with response to adoptive cell therapy
|
US20230399412A1
(en)
|
2020-10-12 |
2023-12-14 |
Nanjing IASO Biotechnology Co., Ltd. |
Antibody and chimeric antigen receptor (car) binding to cd70, and application thereof
|
US20240002505A1
(en)
|
2020-11-01 |
2024-01-04 |
Nanjing IASO Biotechnology Co., Ltd. |
Fully human antibody targeting cd5, and fully human chimeric antigen receptor (car) and application thereof
|
EP4243937A2
(en)
|
2020-11-13 |
2023-09-20 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
|
EP4257617A1
(en)
|
2020-12-01 |
2023-10-11 |
Cure Genetics Co., Ltd |
Antigen-binding protein targeting cd70 and use thereof
|
US11883432B2
(en)
|
2020-12-18 |
2024-01-30 |
Century Therapeutics, Inc. |
Chimeric antigen receptor system with adaptable receptor specificity
|
TW202241479A
(en)
|
2020-12-30 |
2022-11-01 |
美商安迅生物製藥公司 |
Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen
|
CN112321713B
(en)
*
|
2020-12-31 |
2021-05-25 |
北京艺妙神州医药科技有限公司 |
anti-BCMA antibody and application thereof
|
US20240050568A1
(en)
|
2021-01-12 |
2024-02-15 |
Nanjing IASO Biotechnology Co., Ltd. |
Fully human single-domain tandem chimeric antigen receptor (car) targeting cd5, and use thereof
|
CN117693508A
(en)
|
2021-03-03 |
2024-03-12 |
朱诺治疗学股份有限公司 |
Combination of T cell therapy and DGK inhibitors
|
WO2022221737A1
(en)
|
2021-04-16 |
2022-10-20 |
Juno Therapeutics, Inc. |
T cell therapy in patients who have had prior stem cell transplant
|
KR20230171468A
(en)
|
2021-04-16 |
2023-12-20 |
셀진 코포레이션 |
Combination therapy with BCMA-directed T cell therapy
|
TW202309294A
(en)
|
2021-04-27 |
2023-03-01 |
瑞士商諾華公司 |
Viral vector production system
|
JP2024517863A
(en)
|
2021-05-06 |
2024-04-23 |
ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
Methods for stimulating and transducing cells
|
BR112023024804A2
(en)
|
2021-05-28 |
2024-02-15 |
Glaxosmithkline Ip Dev Ltd |
COMBINATION THERAPIES TO TREAT CANCER
|
KR20240040786A
(en)
|
2021-08-03 |
2024-03-28 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
Biopharmaceutical compositions and stable isotope labeled peptide mapping methods
|
WO2023019226A1
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
AU2022325231A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
CA3227108A1
(en)
|
2021-08-11 |
2023-02-16 |
Xiaomeng HU |
Genetically modified primary cells for allogeneic cell therapy
|
AU2022325955A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
WO2023021113A1
(en)
|
2021-08-18 |
2023-02-23 |
Julius-Maximilians-Universität Würzburg |
Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs)
|
CA3229746A1
(en)
|
2021-08-20 |
2023-02-23 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
WO2023025208A1
(en)
|
2021-08-24 |
2023-03-02 |
赛斯尔擎生物技术(上海)有限公司 |
Method for modifying cell
|
CN117858943A
(en)
|
2021-08-24 |
2024-04-09 |
赛斯尔擎生物技术(上海)有限公司 |
T cell products and uses thereof
|
CA3233953A1
(en)
|
2021-10-05 |
2023-04-13 |
Matthew Bruce |
Combination therapies for treating cancer
|
CN114015674A
(en)
|
2021-11-02 |
2022-02-08 |
辉二(上海)生物科技有限公司 |
Novel CRISPR-Cas12i system
|
WO2023081735A1
(en)
|
2021-11-03 |
2023-05-11 |
Celgene Corporation |
Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma
|
WO2023079494A1
(en)
|
2021-11-03 |
2023-05-11 |
Janssen Biotech, Inc. |
Corticosteriod reduction in treatment with anti-cd38 antibodies
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
WO2023129929A1
(en)
|
2021-12-30 |
2023-07-06 |
Tr1X, Inc. |
Cd4+ t cells expressing il-10 and chimeric antigen receptors and uses thereof
|
WO2023130040A2
(en)
|
2021-12-31 |
2023-07-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T cell therapy with vaccination as a combination immunotherapy against cancer
|
WO2023144702A1
(en)
|
2022-01-25 |
2023-08-03 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy for cancer
|
WO2023147515A1
(en)
|
2022-01-28 |
2023-08-03 |
Juno Therapeutics, Inc. |
Methods of manufacturing cellular compositions
|
WO2023158836A1
(en)
|
2022-02-17 |
2023-08-24 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
WO2023213969A1
(en)
|
2022-05-05 |
2023-11-09 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
WO2023220641A2
(en)
|
2022-05-11 |
2023-11-16 |
Juno Therapeutics, Inc. |
Methods and uses related to t cell therapy and production of same
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
WO2023230548A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
WO2023230581A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Methods of manufacturing t cell therapies
|
WO2023230512A1
(en)
|
2022-05-26 |
2023-11-30 |
2Seventy Bio, Inc. |
Compositions for maintaining lentiviral vector and uses thereof
|
WO2024031091A2
(en)
|
2022-08-05 |
2024-02-08 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for gprc5d and bcma
|
WO2024040195A1
(en)
|
2022-08-17 |
2024-02-22 |
Capstan Therapeutics, Inc. |
Conditioning for in vivo immune cell engineering
|
WO2024054944A1
(en)
|
2022-09-08 |
2024-03-14 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|